Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.46 |
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 3/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14400827 | 0.90 | ALDH1A1 (0.46) | KDM4EADRA1AALDH1A1PAOXCASP2 | |
| SCHEMBL861001 | 0.88 | KDM4E (0.62) | KDM4EMAPK1HIF1AADRA1AALDH1A1 | |
| SCHEMBL10825246 | 0.87 | EPHX2 (0.55) | KDM4EMAPK1ADRA1AALDH1A1CASP2 | |
| SCHEMBL21695694 | 0.84 | KDM4E (0.68) | KDM4EMAPK1HIF1AADRA1AALDH1A1 | |
| SCHEMBL861659 | 0.80 | EPHX2 (0.46) | KDM4EMAPK1HIF1AADRA1AALDH1A1 | |
| SCHEMBL12085640 | 0.80 | PAOX (0.51) | KDM4EALDH1A1PAOX | |
| SCHEMBL24067534 | 0.79 | ADRA1A (0.85) | KDM4EMAPK1HIF1AADRA1APAOX | |
| SCHEMBL19960886 | 0.79 | CASP2 (0.71) | KDM4EMAPK1HIF1AADRA1ACASP2 | |
| SCHEMBL19960974 | 0.79 | CASP2 (0.71) | KDM4EMAPK1HIF1AADRA1ACASP2 | |
| SCHEMBL23735533 | 0.79 | KDM4E (0.61) | KDM4EMAPK1HIF1AADRA1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865130-B2 | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | VANDERBILT UNIVERSITY (US) | 2014-10-21 | — | — | US | disclosed |
| US-8143302-B2 | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | VANDERBILT UNIVERSITY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2010-10-07 | — | — | US | disclosed |
| US-7736624-B2 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | UNIV VANDERBILT (US) | 2010-06-15 | — | — | US | disclosed |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | VANDERBILT UNIVERSITY (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | PTGS2, PTGES2, PTGER2 | KDM4E 4585/4885MAPK1 4533/4885HIF1A 899/4885 |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | PTGES2, PTGS2, PTGER2 | KDM4E 4440/4885MAPK1 3292/4885HIF1A 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.